Welcome to our dedicated page for Goodrx Holdings news (Ticker: GDRX), a resource for investors and traders seeking the latest updates and insights on Goodrx Holdings stock.
GoodRx Holdings, Inc. operates a digital healthcare platform focused on prescription and medication savings in the United States. Company news commonly covers prescription transaction revenue, retail pharmacy trends, negotiated discount pricing, PBM relationships, and the expansion of Pharma Direct manufacturer programs that connect branded drug discounts to consumers at the pharmacy counter.
GoodRx updates also include self-pay pricing arrangements for GLP-1 and other branded medications, subscription health services such as condition-specific programs, earnings releases, business outlook commentary, and partnerships with pharmaceutical manufacturers, pharmacies, payers, and healthcare professionals.
GoodRx (Nasdaq: GDRX) reported Q1 2026 results: revenue $194.0M, net income $1.2M, adjusted EBITDA $58.3M (30.0% margin), and adjusted net income $23.0M (11.9% margin).
Pharma Direct revenue grew 82% to $52.2M; subscription revenue rose 16% to $24.4M. Management raised FY2026 revenue guidance to $765–$785M and expects adjusted EBITDA > $235M.
GoodRx (NASDAQ: GDRX) is adding Novo Nordisk’s Ozempic pill (oral semaglutide) to its platform with nationwide self-pay pricing. Eligible patients can access the 1.5mg dose for $149/month, 4mg for $199/month, and 9mg for $299/month. The move expands GoodRx’s semaglutide offerings and aims to provide an oral alternative to injectable treatment at retail pharmacies.
GoodRx (Nasdaq: GDRX) will release first quarter 2026 results after U.S. markets close on Wednesday, May 6, 2026.
Management will host a conference call and webcast on Thursday, May 7, 2026 at 5:00 a.m. PT (8:00 a.m. ET); materials and an archived webcast will be available on the investor relations website.
GoodRx (Nasdaq: GDRX) announced Wegovy® HD (semaglutide 7.2 mg) is available to eligible self-pay patients at a $399 per month price, with two- and three-month supplies at $798 and $1,197 respectively. GoodRx for Weight Loss offers eligibility assessment, provider visits, and prescription support nationwide.
The offering aims to expand access to FDA-approved GLP-1 dosing with upfront pricing and pharmacy fulfillment through GoodRx’s platform.
GoodRx (Nasdaq: GDRX) expanded access to Eli Lilly’s new oral GLP-1 Foundayo (orforglipron) and to Zepbound KwikPen. Eligible self-pay patients can access Foundayo starting at $149/month and Zepbound KwikPen starting at $299/month at more than 70,000 pharmacies nationwide. GoodRx said these offerings provide transparent cash pricing and nationwide pharmacy access, supporting direct-to-consumer launch models as insurance coverage for GLP-1 treatments remains inconsistent.
GoodRx reported a platform reach of nearly 25 million consumers and highlighted its role connecting manufacturers, pharmacies, clinicians, and patients.
GoodRx (Nasdaq: GDRX) and Viatris announced a collaboration to make 17 established brand medications more affordable in the U.S. Eligible commercially insured patients may pay $0–$4 on select Viatris drugs; cash prices can be discounted up to 85% off at > 70,000 pharmacies. Brands included: Lipitor, Celebrex, Viagra, and Norvasc. GoodRx cites nearly 25 million annual users and says the platform has helped save over $100 billion since 2011. The program aims to expand access and support adherence for established brands, including those navigating loss of exclusivity.
GoodRx (Nasdaq: GDRX) will enable self-insured employers to subsidize Eli Lilly’s Employer Connect price of $449 for Zepbound® (tirzepatide) KwikPen across all doses, applying employer contributions in real time at the pharmacy counter.
GoodRx Employer Direct integrates manufacturer discounted pricing, employer funding, and optional telemedicine to simplify prescribing, fulfillment, and reduce employee out-of-pocket costs while complementing—but not replacing—traditional health plans.
GoodRx (Nasdaq: GDRX) reported Q4 2025 revenue of $194.8M and full-year 2025 revenue of $796.9M. Full-year adjusted EBITDA was $270.5M with an adjusted EBITDA margin of 33.9%. Pharma Direct revenue grew 41% to $151.4M. Net income for 2025 was $30.4M. The company repurchased 48.9M shares for $217.4M and finished 2025 with $261.8M cash and $495.0M debt. Management provided FY2026 revenue guidance of $750M–$780M and Adjusted EBITDA above $230M. A conference call is scheduled for February 26, 2026.
GoodRx (Nasdaq: GDRX) launched GoodRx Employer Direct on February 24, 2026, offering employers targeted subsidies to lower employee out-of-pocket costs for high-impact brand medications, including GLP-1s like Wegovy. Employer Direct also offers branded telemedicine solutions that integrate clinical care, prescribing, and pharmacy fulfillment while complementing existing health plans.
The program began with initial employer partners, including Hy-Vee, and applies employer contributions at the pharmacy counter to reduce costs without altering core plan structures.
GoodRx (Nasdaq: GDRX) is a core integration partner for TrumpRx, powering pricing for leading brand medications at launch.
GoodRx will serve as the integrated pricing source for Pfizer for over 30 essential brand medications, offering savings up to 85% and averaging 50% on many primary care and select specialty treatments. GoodRx says its platform reduces operational lift for manufacturers and enables rapid deployment of discounted cash pricing nationally.